Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day

Background.  Various in vitro studies have shown fluoxetine inhibits multiple variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen causing the coronavirus disease 2019 (COVID-19) worldwide pandemic and multiple observational clinical studies have shown that patients...

Descripción completa

Detalles Bibliográficos
Autor principal: Eugene, Andy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561539/
https://www.ncbi.nlm.nih.gov/pubmed/36262792
http://dx.doi.org/10.12688/f1000research.53275.3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561539/
https://www.ncbi.nlm.nih.gov/pubmed/36262792
http://dx.doi.org/10.12688/f1000research.53275.3

Ejemplares similares